Table 1 The demographic and disease characteristics information of all patients
Characteristics | Group A | Group B | Group C | Overall | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Relapse 29 (50.88%) | Not Relapse 28 (49.12%) | P | Relapse 22 (31.43%) | Not Relapse 48 (68.57%) | P | Relapse 6 (13.64%) | Not Relapse 38 (86.36%) | P | Relapse 57 (33.33%) | Not Relapse 114 (66.67%) | P | |
Age*, mean ± sd | 39.07 ± 13.72 | 37.18 ± 13.69 | 0.605 | 37.00 ± 15.49 | 34.21 ± 12.36 | 0.421 | 29.17 ± 9.80 | 29.58 ± 13.20 | 0.942 | 38.81 ± 16.72 | 33.39 ± 13.20 | 0.083 |
Gender, n (%) | ||||||||||||
Male | 25 (86.21%) | 20 (71.43%) | 0.207 | 20 (90.90%) | 38 (79.17%) | 0.195 | 4 (66.67%) | 32 (84.21%) | 0.297 | 49 (85.96%) | 90 (78.95%) | 0.267 |
Female | 4 (13.80%) | 8 (28.57%) | 2 (9.91%) | 10 (20.83%) | 2 (33.33%) | 6 (15.79%) | 8 (14.04%) | 24 (21.05%) | ||||
Duration of Symptoms, median(interquartile range), (month) | 6.00(22.33) | 10.00(21.33) | 0.501 | 36.50(47.83) | 12.17(31.75) | 0.062 | 30.41(112.04) | 12.17(31.00) | 0.256 | 36.5(47.83) | 12.17(31.75) | 0.407 |
¾Location**, n (%) | ||||||||||||
L1 | 13 (44.83%) | 14 (50.00%) | 0.493 | 12 (54.53%) | 21 (43.75%) | 0.267 | 2 (33.33%) | 18 (47.37%) | 0.785 | 27 (47.37%) | 53 (46.49%) | 0.993 |
L2 | 4 (13.79%) | 1 (3.57%) | 2 (9.91%) | 8 (16.67%) | 0 (0.00%) | 3 (7.89%) | 6 (10.53%) | 12 (10.53%) | ||||
L3 | 12 (41.38%) | 13 (46.43%) | 8 (36.36%) | 19 (39.58%) | 4 (66.67%) | 17 (44.74%) | 24 (42.11%) | 49 (42.98%) | ||||
Behaviour**,n (%) | ||||||||||||
B1 | 21 (72.41%) | 22 (78.57%) | 0.871 | 15 (68.18%) | 39 (81.25%) | 0.369 | 3 (50.00%) | 29 (76.32%) | 0.106 | 39 (68.42%) | 90 (78.95%) | 0.602 |
B2 | 1 (3.45%) | 1 (3.57%) | 4 (18.18%) | 4 (8.33%) | 1 (16.67%) | 7 (18.42%) | 6 (10.53%) | 12(10.53%) | ||||
B3 | 7 (24.14%) | 5 (17.86%) | 3 (13.64%) | 5 (10.42%) | 2 (33.33%) | 2 (5.26%) | 12 (21.05%) | 12(10.53%) | ||||
Perianal disease, n (%) | ||||||||||||
Yes | 5 (17.24%) | 3 (10.71%) | 0.706 | 7 (31.82%) | 9 (18.75%) | 0.182 | 0 (0.00%) | 8 (21.05%) | 0.276 | 12 (21.05%) | 20 (17.54%) | 0.579 |
No | 24 (82.76%) | 25 (89.29%) | 15 (68.18%) | 39 (81.25%) | 6 (100.00%) | 30 (78.95%) | 45 (78.95%) | 94 (82.46%) | ||||
CDAI | 336.41 ± 102.95 | 317.18 ± 85.22 | 0.446 | 322.45 ± 97.66 | 350.50 ± 123.01 | 0.310 | 355.33 ± 97.66 | 332.21 ± 103.71 | 0.605 | 340.44 ± 103.59 | 329.17 ± 101.09 | 0.496 |
SES-CD | 5.90 ± 2.51 | 5.70 ± 2.08 | 0.752 | 6.32 ± 1.96 | 6.67 ± 2.10 | 0.513 | 4.33 ± 3.39 | 5.97 ± 2.35 | 0.143 | 5.92 ± 2.37 | 6.20 ± 2.20 | 0.446 |
Previous treatment (%) | ||||||||||||
Anti-infective | 3 (10.34%) | 1 (3.57%) | 0.299 | 2 (9.09%) | 4 (8.33%) | 0.486 | 0 (0.00%) | 2 (5.26%) | 0.531 | 5 (8.77%) | 7 (6.14%) | 0.104 |
Symptomatic treatment*** | 8 (27.59%) | 14 (50.00%) | 10 (45.45%) | 21 (43.75%) | 1 (16.67%) | 16 (42.11%) | 19 (33.33%) | 51 (44.74%) | ||||
Anti-infective and Symptomatic treatment | 8 (27.59%) | 4 (14.29%) | 3 (13.64%) | 2 (4.17%) | 1 (16.67%) | 4 (10.53%) | 12 (21.05%) | 10 (8.77%) | ||||
None | 10 (34.48%) | 9 (32.14%) | 7 (31.82%) | 21 (43.75%) | 4 (66.67%) | 16 (42.11%) | 21 (36.84%) | 46 (40.35%) | ||||